GLM-101
- Generic Name
- GLM-101
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Glycomine, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06657859
- Locations
- 🇪🇸
Hospital Sant Joan de Déu, Barcelona, Spain
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Glycomine, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05549219
- Locations
- 🇬🇧
Great Ormond Street Hospital, London, United Kingdom
🇺🇸Clinical Research of West Florida, Tampa, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath